Efficacy of re-treatment by peginterferon alpha-2a and ribavirin in a child with hepatitis C

J Infect Chemother. 2014 Jul;20(7):443-5. doi: 10.1016/j.jiac.2014.02.004. Epub 2014 May 1.

Abstract

Background: There is currently no consensus treatment for children non-responsive to peginterferon (Peg-IFN) and ribavirin.

Case presentation: Here, we present a Japanese child with chronic hepatitis C with fibrosis, who did not respond to Peg-IFN α-2b but responded to Peg-IFN α-2a with ribavirin, accompanied with fluvastatin. To date, there has been no reported case of re-treatment in children. The early viral response occurred soon after starting treatment using Peg-IFN α-2a/ribavirin plus fluvastatin.

Conclusion: Our result indicates that when treatment by Peg-IFN α-2b/ribavirin combination therapy is not efficient, combination therapy using Peg-IFN α-2a/ribavirin plus fluvastatin should be considered in children with advanced liver change.

Keywords: Fluvastatin; Non-responsive; Peginterferon; Ribavirin; Sustained virologic response.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Child
  • Drug Therapy, Combination / methods
  • Fatty Acids, Monounsaturated / therapeutic use
  • Fluvastatin
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Indoles / therapeutic use
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Male
  • Polyethylene Glycols / therapeutic use*
  • Recombinant Proteins / therapeutic use
  • Ribavirin / therapeutic use*
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Fatty Acids, Monounsaturated
  • Indoles
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • Fluvastatin
  • peginterferon alfa-2b